Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
6.59
-0.40 (-5.72%)
Mar 31, 2025, 1:13 PM EDT - Market open
Company Description
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies.
The company’s clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy.
It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Oct 2, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 118 |
| CEO | Clay Siegall |
Contact Details
Address: 18702 N. Creek Parkway, Suite 100 Bothell, Washington 98011 United States | |
| Phone | 425 939 7410 |
| Website | immunome.com |
Stock Details
| Ticker Symbol | IMNM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001472012 |
| CUSIP Number | 45257U108 |
| ISIN Number | US45257U1088 |
| Employer ID | 77-0694340 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Clay B. Siegall Ph.D. | Chairman, President and Chief Executive Officer |
| Dr. Jack Higgins Ph.D. | Chief Scientific Officer |
| Dr. Robert J. Lechleider M.D. | Chief Medical Officer |
| Max Rosett | Chief Financial Officer |
| Dr. Philip Tsai | Chief Technical Officer |
| Sandra G. Stoneman Esq., J.D. | Chief Legal Officer, General Counsel and Corporate Secretary |
| Kinney Horn | Chief Business Officer |
| Roee Shahar | Executive Vice President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 19, 2025 | 10-K | Annual Report |
| Mar 19, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 4, 2025 | SCHEDULE 13D/A | Filing |
| Feb 3, 2025 | SCHEDULE 13G | Filing |
| Jan 30, 2025 | SCHEDULE 13G/A | Filing |
| Jan 30, 2025 | 8-K | Current Report |
| Jan 30, 2025 | 424B5 | Filing |
| Jan 29, 2025 | 424B5 | Filing |